Clarity Pharmaceuticals opens SARTATE™ neuroblastoma clinical trial
Sydney, Australia 23 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has opened its trial of 67Cu-SARTATE™ for paediatric patients with neuroblastoma at Memorial Sloan Kettering Cancer Center (MSK) in New York City and recruitment has commenced. “We are very excited to…